Tagged with GEN

UAE With a combined experience of over five decades in the pharmaceutical industry including senior executive roles at companies such as Merck and Janssen, Karim Smaira and Kamel Ghammachi have come a long way with Genpharm, the Dubai-based market access company they founded in 2012. After years of learning the ins…

Canada Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for Alzheimer’s Disease (AD) treatments, and how Canada is playing a leading role in the development of the next generation of AD therapies.   We’re at the advent of a potential landmark…

Mexico Dr David Kershenobich Stalnikowitz, director-general of the Salvador Zubirán National Institute of Medical Sciences and Nutrition (INCMNSZ) shares the many new initiatives the Institute has introduced in the past couple of years, the new focus on primary care provision in line with government priorities, and the ongoing construction of their…

Opinion Jonathan Kimball of the Association for Accessible Medicines (AAM) in the USA outlines why the signing of the US-Mexico-Canada Agreement (USMCA) in January 2020 may mark a turning point for greater access to generic and biosimilar medicines globally.   US trading partners should take note. There is no longer a…

Belgium Teva Pharma Belgium’s Eric Deschepper outlines how the global group’s restructuring has impacted its Belgian operations, its realignment from a pure generics to a specialty pharma player, and how the company is uniquely positioned to help Belgium achieve its healthcare goals.   We are in fact on both sides of…

Czech Republic Martin Puchwein, country president for Novartis Group Czech Republic, and general manager for pharma, shares his perspectives on launching innovative drugs in the country, including some new therapeutic approaches such as cell and gene therapies. Puchwein also discusses Novartis’ ambition to transform its corporate culture towards becoming an organization where…

UAE The UAE’s distinctive willingness to embrace innovation and the ‘can-do’ spirit of authorities marks the country out as worthy of attention as an initial product launch platform.   “Along with fellow GCC members, Kuwait and Saudi Arabia, the UAE is notable for its accelerated regulatory pathways. Due to these mechanisms,…

Colombia Tecnoquimicas (TQ), the largest domestic player in Colombia’s USD 4.6 billion pharma market, announced a swathe of manufacturing investments in late 2019, taking its spending on plants and equipment in the 2018-2022 period to over USD 200 million.   According to Company President Francisco José Barberi, TQ’s investments will expand…

UAE The Dubai Health Authority, the government body responsible for overseeing Dubai’s health system, is working full speed as the 2021 mark laid by the Dubai Health Strategy 2021 approaches. Director General HE Humaid Al Qutami, explains how the organization is working to provide the highest quality of medical care to…

Mexico Juan de Villafranca, executive director of the Asociacion Mexicana de Laboratorios Farmaceuticos (AMELAF), shares the exciting new initiatives he has launched in the past two years of his term; the importance and strength of AMELAF as the representative association of 44 100 percent Mexican-owned pharmaceutical manufacturers; and the potential and…

Romania Valentina Băicuianu and Adrian Grecu of the APMGR, share their insights on the deteriorating environment for generics in Romania, with unfavourable pricing methodology and a rising and an unpredictable clawback tax. They reveal the solutions that the generics industry has proposed to authorities and outline their continued endeavours to convince…

UAE As Fujifilm, the iconic Japanese photography and imaging company, continues to expand into healthcare, it is betting heavily on the Middle East and Africa (MEA). Chihiro Sasaki, healthcare division manager in the region, explains the company’s footprint in MEA, its efforts to help the region combat chronic diseases through innovative…